These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

834 related items for PubMed ID: 23072702

  • 1. Coronary artery bypass grafting after aprotinin: are we doing better?
    Beckerman Z, Shopen Y, Alon H, Cohen O, Nir RR, Adler Z, Bolotin G.
    J Thorac Cardiovasc Surg; 2013 Jan; 145(1):243-8. PubMed ID: 23072702
    [Abstract] [Full Text] [Related]

  • 2. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
    Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R.
    Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
    [Abstract] [Full Text] [Related]

  • 3. Aprotinin is not associated with postoperative renal impairment after primary coronary surgery.
    Lindvall G, Sartipy U, Ivert T, van der Linden J.
    Ann Thorac Surg; 2008 Jul; 86(1):13-9. PubMed ID: 18573391
    [Abstract] [Full Text] [Related]

  • 4. Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.
    Vonk AB, Meesters MI, Schats J, Romijn JW, Jansen EK, Boer C.
    Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):135-9. PubMed ID: 21075830
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Perioperative renal outcome in cardiac surgical patients with preoperative renal dysfunction: aprotinin versus epsilon aminocaproic acid.
    Maslow AD, Chaudrey A, Bert A, Schwartz C, Singh A.
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):6-15. PubMed ID: 18249324
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Conference discussion: Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.
    Wahba A, Vonk A, Bidstrup B.
    Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):139-40. PubMed ID: 21322159
    [No Abstract] [Full Text] [Related]

  • 14. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.
    Casati V, Guzzon D, Oppizzi M, Bellotti F, Franco A, Gerli C, Cossolini M, Torri G, Calori G, Benussi S, Alfieri O.
    J Thorac Cardiovasc Surg; 2000 Sep; 120(3):520-7. PubMed ID: 10962414
    [Abstract] [Full Text] [Related]

  • 15. Current antifibrinolytic therapy for coronary artery revascularization.
    Trudell J, McMurdy N.
    AANA J; 2008 Apr; 76(2):121-4. PubMed ID: 18478817
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery.
    Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM.
    Transfusion; 2006 Mar; 46(3):327-38. PubMed ID: 16533273
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.